Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy

Area of Science:

• Oncology
• Gene Therapy
• Molecular Biology

Background:

• Antiangiogenic therapy shows promise for cancer treatment.
• Endogenous angiogenesis inhibitors (angiostatin, endostatin, TIMPs) are effective in animal models.
• Recombinant protein delivery faces challenges for long-term administration.

Purpose of the Study:

• To develop a gene therapy approach for delivering angiogenesis inhibitors.
• To create and characterize eukaryotic expression constructs for antiangiogenic agents.
• To enable sustained therapeutic protein production within the body.

Main Methods:

• Generated eukaryotic expression constructs for murine angiostatin, endostatin, and human TIMP-2.
• Utilized the HCMV promoter/enhancer for strong gene expression.
• Validated protein expression and secretion in vitro using transcription/translation and cell transfection (293T cells) followed by Western blotting and radioimmunoprecipitation.

Main Results:

• Successfully generated and characterized expression constructs for key angiogenesis inhibitors.
• Confirmed in vitro expression and secretion of functional antiangiogenic proteins.
• Demonstrated the feasibility of delivering these inhibitors via gene therapy vectors.

Conclusions:

• Eukaryotic expression constructs for angiostatin, endostatin, and TIMP-2 are viable for gene therapy.
• These constructs can be delivered via plasmid DNA or viral vectors (retroviral, AAV).
• This approach offers a potential alternative to recombinant protein therapy for cancer treatment.